Clients in the media Clients IN the MEDIA

Ensuring your story is visible.

Obesity drugmaker lands first biopharma uplisting onto Nasdaq since last summer

But behind the industry’s first uplisting of 2024, from San Diego biotech Skye Bioscience, is investors’ interest in an area of drug R&D that every therapeutics developer wants in on right now: the next wave of obesity medications.


How Can a Treatment Become a Vaccine??? Dr. Peter DeMuth, Chief Scientific Officer at Elicio Therapeutics

Dr. Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, discusses the revolutionary approach of detecting cancer at its earliest stages through circulating tumor DNA (ctDNA) tests. Highlighting their innovative treatment method, which aims to train the body’s immune cells to recognize and destroy cancer cells, the episode explores the potential transition from treatment to vaccine, offering hope for more effective and durable solutions.


AACR 2024: What Cancer Researchers Are Talking About

Florida-based Syncromune presented the first-ever clinical data from SYNC-T, a personalized platform therapy that uses a drug-device combination, in metastatic castration-resistant prostate cancer.


ACC24 Roundup: Novo, Ionis Tout Cardio Victories and Boehringer, Lilly Disappoint

Arrowhead Pharmaceuticals unveiled Phase IIb data for its investigational RNAi therapy plozasiran at ACC24, demonstrating steep triglyceride reductions at 24 weeks in patients with severely elevated triglyceride levels who are at risk of developing acute pancreatitis.

NeuroVoices: Aki Ko, on mRNA Therapeutics for Duchenne Muscular Dystrophy

Aki Ko, chief executive officer at Elixirgen Therapeutics, sat down with NeurologyLive® at the conference to discuss the promise behind the therapy and why it can be successful in treating DMD.


Eying Up The Era Of Topical Biologics

Claris has found dHGF stable for three years at refrigeration temperatures and three months at room temperature


Madrigal landed a historic MASH approval. What comes next for biotechs in pursuit?

“Aligos is not only supportive of the progress this approval represents but happy to see this class validated as we begin the phase 2a trial of our own highly potent and selective THR-β agonist, ALG-055009.”

Austin American

What’s the future of health? SXSW panels talk AI, tech, personalized medicine and more

With global warming, fungi have become more adapted to higher temperatures like the human body, and with the use of fungicides in farming, fungi are more resistant to treatments.